Doxycycline-rifampin versus doxycycline-streptomycin in treatment of human brucellosis due to Brucella melitensis. The GECMEI Group. Grupo de Estudio de Castilla-la Mancha de Enfermedades Infecciosas.

Doxycycline-rifampin versus doxycycline-streptomycin in treatment of human brucellosis due to Brucella melitensis. The GECMEI Group. Grupo de Estudio de Castilla-la Mancha de Enfermedades Infecciosas.

Item

http://www.wikidata.org/entity/Q35118444

Q35118444

about

Antibiotics for treating human brucellosis Antibiotics for treating human brucellosis The economic impact of a bioterrorist attack: are prevention and postattack intervention programs justifiable?Doxycycline plus streptomycin versus ciprofloxacin plus rifampicin in spinal brucellosis [ISRCTN31053647].Identification of Brucella by MALDI-TOF mass spectrometry. Fast and reliable identification from agar plates and blood cultures Use of aminoglycosides in treatment of infections due to intracellular bacteria Human brucellosis in Macedonia - 10 years of clinical experience in endemic region.Systematic review and meta-analysis of randomized clinical trials in the treatment of human brucellosis Brucella prosthetic joint infection: a report of 3 cases and a review of the literature.Treatment of human brucellosis with doxycycline and gentamicin.Current development and future prospects in chemotherapy of tuberculosis Brucella arteritis: clinical manifestations, treatment, and prognosis The pathophysiology of inhalational brucellosis in BALB/c mice.Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis Quinolones for treatment of human brucellosis: critical review of the evidence from microbiological and clinical studies.Future trends in human brucellosis treatment.Microarray-based long oligonucleotides probe designed for Brucella Spp. detection and identification of antibiotic susceptibility pattern.Therapeutic options for human brucellosis.Treatment of brucellosis: a systematic review of studies in recent twenty years.Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs.New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.Nondividing but metabolically active gamma-irradiated Brucella melitensis is protective against virulent B. melitensis challenge in mice.A sporadic outbreak of human brucellosis in Korea.Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis.[A 37-year-old patient with fever, dyspnea and elevated transaminases after a stay in Mexico].Clinical findings, therapeutic approach, and outcome of brucellar vertebral osteomyelitis.Human brucellosis in a nonendemic country: a report from Germany, 2002 and 2003.Infections in Hispanic immigrants.Epididymoorchitis due to Brucella mellitensis: a retrospective study of 59 patients.A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.Species-specific PCR for the Diagnosis and Determination of Antibiotic Susceptibilities of Brucella Strains Isolated from Tehran, Iran.Effect of Medium pH on Antibiotic Activity against Syrian Brucella spp. Isolates.Acute prostatitis as an uncommon presentation of brucellosis.A comparative trial of three therapeutic regimens: ciprofloxacin-rifampin, ciprofloxacin-doxycycline and doxycycline-rifampin in the treatment of brucellosis.Rifampicin versus streptomycin for brucellosis treatment in humans: A meta-analysis of randomized controlled trials.First case of cervical epidural abscess caused by brucellosis in Saudi Arabia: A case report and literature review.

P2860

Q24198231-57A2E30C-49C8-4754-BB54-08D3EB4780E5 Q24243506-72BADBDF-E1DF-472B-868D-630FBDF6098D Q30233815-5B239D17-A4D8-4007-9490-83BE5862C06C Q33239526-D4F25FD6-2E57-4489-9918-1E68B52DE37D Q33769422-DFA48000-A54E-4AAE-A3E5-28A3DB16AC8E Q33983252-021C384B-D163-4A3C-8D4D-2AD589190BEF Q34097677-4B5F7C97-B72A-486B-9931-EBE7E4BAD98F Q34185756-5A4D0B50-765E-4C18-8DE8-AB847D2CD378 Q35090511-D48FB44E-86AB-411F-B21A-A88732E4E2CF Q35131054-3380FD69-D0B9-44BC-8D2E-358324FF8154 Q35705874-89A28C0F-397D-4768-8432-FB4ABFFB87C4 Q35841320-B753C018-2431-4954-819E-68F33A3A9BC6 Q36078659-51539DA1-85D0-4AD2-A038-33741A43E4A6 Q36171524-3CD0007C-25CA-418A-A245-1BBB516F0DAC Q36353529-CD33E21E-6376-4D20-9A03-78B26FFF91E8 Q36600269-6A191BAA-AA84-4C96-8473-84F78E405868 Q36950363-8C7E126D-C756-4D54-A170-9E3B6A4FAD8D Q37077636-E5AF623D-9670-453A-A4BC-FF1A591AD785 Q37128458-291E060A-6AF7-4091-8330-71FF7DB7C385 Q37247736-DF760D09-DA79-49AE-84BA-F5BB06E17BF9 Q37346929-C0E24C24-B275-4BE2-A5FD-CAF33F35B51A Q37410370-16E2A905-630F-4292-AC83-97925192EE9D Q37425828-B7A934F0-5517-4364-952C-379D0E7D9BB6 Q37861939-1050683A-3713-4A7E-B7FF-FB657E07E346 Q38852090-E6F0166E-10AF-4C70-985D-F3974A7AC570 Q40359190-0C846C81-EE2D-4F1A-AB02-32230E7E83FE Q40429927-F4152FB0-7113-4507-8EDF-5A7DCA9EEF61 Q40506130-992345A7-50F1-40BE-8136-452B859B5298 Q40581654-81911B95-DB7B-4A8F-84F2-F82DD1888FA7 Q40593604-A5969D3A-F405-4D8E-B211-40546B85B670 Q41475312-314FBEE6-EB09-4D82-A092-C42B2B9733EB Q41574125-C0B3D87F-0A7B-49BE-B96C-14D60946E0CF Q41838695-624AFF45-0355-4FA3-B048-928DB03E5859 Q42176269-2C1700D8-7DF1-45A4-BBFD-781F81479437 Q43275117-9D5117DB-87F2-4275-B2B0-59D4FC391822 Q55221193-D28BBE3F-6A09-47BB-87C7-41A0819EC61B Q55326839-6EF977B3-E0E6-48FE-B852-42FCE8B28D96

P2860

Doxycycline-rifampin versus doxycycline-streptomycin in treatment of human brucellosis due to Brucella melitensis. The GECMEI Group. Grupo de Estudio de Castilla-la Mancha de Enfermedades Infecciosas.

Item

http://www.wikidata.org/entity/Q35118444

description

1995 nî lūn-bûn

@nan

1995 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

1995 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

1995年の論文

@ja

1995年論文

@yue

1995年論文

@zh-hant

1995年論文

@zh-hk

1995年論文

@zh-mo

1995年論文

@zh-tw

1995年论文

@wuu